Stay updated on IMGN632 in BPDCN Clinical Trial
Sign up to get notified when there's something new on the IMGN632 in BPDCN Clinical Trial page.

Latest updates to the IMGN632 in BPDCN Clinical Trial page
- Check4 days agoChange DetectedAdded a consolidated Locations section listing multiple state sites (Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas, Washington) and updated the page revision to v3.3.3. Removed the prior per-state location subsections (e.g., Arizona Locations, California Locations, etc.).SummaryDifference0.9%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedAdded a PubMed auto-fill note for publications and updated the page revision to v3.3.2; the previous PubMed description and the older revision v3.2.0 were removed.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding status notice was removed, but the study details remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedLayout and formatting changes to the study page, with no modification to core content such as title, conditions, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange DetectedUpdated version to v3.2.0 and added government operating-status notice; removed a previously listed condition (CD4+/CD56+ hematodermic neoplasm) and prior version tag. Overall: core content update plus new operational status info.SummaryDifference4%

- Check90 days agoChange DetectedCore terminology and versioning updated: replacing 'Acute lymphoblastic leukemia' with 'Acute lymphoid leukemia' and bumping the revision from v3.0.2 to v3.1.0.SummaryDifference0.2%

Stay in the know with updates to IMGN632 in BPDCN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN632 in BPDCN Clinical Trial page.